BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 914)

  • 1. Overview: maintenance therapy in psychiatry: I. Schizophrenia.
    Davis JM
    Am J Psychiatry; 1975 Dec; 132(12):1237-45. PubMed ID: 914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview: maintenance therapy in psychiatry: II. Affective disorders.
    Davis JM
    Am J Psychiatry; 1976 Jan; 133(1):1-13. PubMed ID: 1108674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication].
    Steuber H; Kind J; Lohrengel S; Müller P
    Arzneimittelforschung; 1978; 28(9):1492-3. PubMed ID: 38806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance antipsychotic drugs do prevent relapse: a reply to Tobias and MacDonald.
    Davis JM; Gosenfeld L; Tsai CC
    Psychol Bull; 1976 May; 83(3):431-47. PubMed ID: 6986
    [No Abstract]   [Full Text] [Related]  

  • 5. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
    Hogarty GE
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Maintenance therapy in schizophrenia -- a brief review of the literature].
    Balla P; Frecska E
    Neuropsychopharmacol Hung; 2012 Sep; 14(3):197-200. PubMed ID: 22987733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
    Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
    Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Schizophrenia: prophylaxis prevents recurrence. Low dose depot neuroleptics--an exit from the "revolving door" psychiatry].
    Fortschr Med Suppl; 1993; 147():1-15. PubMed ID: 9260317
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose selection and comparator drugs in schizophrenia research.
    Kane JM
    J Clin Psychiatry; 2001; 62 Suppl 9():29-32; discussion 33-4. PubMed ID: 11379828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy and the natural course of schizophrenia.
    Davis JM
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments.
    Bosveld-van Haandel LJ; Slooff CJ; van den Bosch RJ
    Acta Psychiatr Scand; 2001 May; 103(5):335-46. PubMed ID: 11380303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance therapy and schizophrenia.
    Leff JP
    Br J Psychiatry; 1975; Spec No 9():55-8. PubMed ID: 241453
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
    Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
    Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
    Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M
    Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.